Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.

Chao AM, Wadden TA, Walsh OA, Gruber KA, Alamuddin N, Berkowitz RI, Tronieri JS

Clinical obesity5 Nov 2019Cited by 8 (Europe PMC)

PMID31691531DOI10.1111/cob.12340PepBankPUB-31691531

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, intensive behavioural therapy plus liraglutide 3.0 mg/day gave 11.5% weight loss at week 52 versus 6.1% with behavioural therapy alone.
In plain wordsIn adults with obesity, adding liraglutide to behavioural therapy led to more weight loss at one year than behavioural therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at week 52, IBT-liraglutide versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioural therapy alone (IBT-alone)
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg/day · 52 weeksAs given in this study (human).
Measurements
Weight loss
11.5%
IBT-liraglutide
Weight loss
6.1%
IBT-alone
Source sentences
Summary
At week 52, participants in the three groups lost 6.1 ± 1.3%, 11.5 ± 1.3% and 11.8 ± 1.3% of initial body weight, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of intensive behavioural therapy (IBT) for obesity (IBT-alone), IBT plus liraglutide 3.0 mg/day (IBT-liraglutide), and IBT-liraglutide combined with 12 weeks of a portion-controlled diet (Multicomponent) on changes in general health-related (HR) quality of life (QoL)…
Summary · context
Adults with obesity (79.3% female; 54.0% white; 44.7% black; mean age = 47.6 ± 11.8 years and body mass index = 38.4 ± 4.9 kg/m² ) were randomized to IBT-alone (n = 50), IBT-liraglutide (n = 50) or Multicomponent (n = 50).
Report a problemFND-3169153101

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, behavioural therapy plus liraglutide plus a portion-controlled diet gave 11.8% weight loss at week 52 versus 6.1% with behavioural therapy alone.
In plain wordsIn adults with obesity, behavioural therapy with liraglutide and a portion-controlled diet led to more weight loss than behavioural therapy alone.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at week 52, Multicomponent versus IBT-alone
Study
n: not reported in source
Comparator
Intensive behavioural therapy alone (IBT-alone)
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.8%
Multicomponent
Weight loss
6.1%
IBT-alone
Source sentences
Summary
At week 52, participants in the three groups lost 6.1 ± 1.3%, 11.5 ± 1.3% and 11.8 ± 1.3% of initial body weight, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of intensive behavioural therapy (IBT) for obesity (IBT-alone), IBT plus liraglutide 3.0 mg/day (IBT-liraglutide), and IBT-liraglutide combined with 12 weeks of a portion-controlled diet (Multicomponent) on changes in general health-related (HR) quality of life (QoL)…
Summary · context
Adults with obesity (79.3% female; 54.0% white; 44.7% black; mean age = 47.6 ± 11.8 years and body mass index = 38.4 ± 4.9 kg/m² ) were randomized to IBT-alone (n = 50), IBT-liraglutide (n = 50) or Multicomponent (n = 50).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3169153102
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, both liraglutide-treated groups (IBT-liraglutide and Multicomponent) were more likely than IBT-alone to achieve clinically meaningful improvements in total weight-related quality of life.
In plain wordsIn adults with obesity, both groups that took liraglutide were more likely than the behavioural-therapy-only group to report meaningfully better weight-related quality of life.
Peptide
Liraglutide
Outcome
IncreaseClinically meaningful improvement in weight-related quality of life
Study
n: not reported in source
Comparator
Intensive behavioural therapy alone (IBT-alone)
Outcome group
Quality of life · Whole body
Source sentences
Summary
Both liraglutide-treated groups were significantly more likely than IBT-alone to achieve clinically meaningful improvements in total weight-related QoL.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of intensive behavioural therapy (IBT) for obesity (IBT-alone), IBT plus liraglutide 3.0 mg/day (IBT-liraglutide), and IBT-liraglutide combined with 12 weeks of a portion-controlled diet (Multicomponent) on changes in general health-related (HR) quality of life (QoL)…
Summary · context
Adults with obesity (79.3% female; 54.0% white; 44.7% black; mean age = 47.6 ± 11.8 years and body mass index = 38.4 ± 4.9 kg/m² ) were randomized to IBT-alone (n = 50), IBT-liraglutide (n = 50) or Multicomponent (n = 50).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3169153103
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, both liraglutide-treated groups achieved greater improvements than IBT-alone in weight-related public distress.
In plain wordsIn adults with obesity, both groups that took liraglutide reported larger improvements than the behavioural-therapy-only group in distress about their weight in public.
Peptide
Liraglutide
Outcome
IncreaseWeight-related public distress
Study
n: not reported in source
Comparator
Intensive behavioural therapy alone (IBT-alone)
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
They also both achieved greater improvements than IBT-alone in weight-related public distress
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of intensive behavioural therapy (IBT) for obesity (IBT-alone), IBT plus liraglutide 3.0 mg/day (IBT-liraglutide), and IBT-liraglutide combined with 12 weeks of a portion-controlled diet (Multicomponent) on changes in general health-related (HR) quality of life (QoL)…
Summary · context
Adults with obesity (79.3% female; 54.0% white; 44.7% black; mean age = 47.6 ± 11.8 years and body mass index = 38.4 ± 4.9 kg/m² ) were randomized to IBT-alone (n = 50), IBT-liraglutide (n = 50) or Multicomponent (n = 50).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3169153104
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity, both liraglutide-treated groups achieved greater improvements than IBT-alone in general mental health on the SF-36 mental component summary.
In plain wordsIn adults with obesity, both groups that took liraglutide reported larger mental health improvements than the behavioural-therapy-only group.
Peptide
Liraglutide
Outcome
IncreaseSF-36 mental component summary score
Study
n: not reported in source
Comparator
Intensive behavioural therapy alone (IBT-alone)
Outcome group
Quality of life · Mental health and mood
Source sentences
Summary
They also both achieved greater improvements than IBT-alone in weight-related public distress and in general mental health, as measured by the SF-36 mental component summary score.
2 context sentences(design, population, supporting numbers)
Summary · context
This study examined the effects of intensive behavioural therapy (IBT) for obesity (IBT-alone), IBT plus liraglutide 3.0 mg/day (IBT-liraglutide), and IBT-liraglutide combined with 12 weeks of a portion-controlled diet (Multicomponent) on changes in general health-related (HR) quality of life (QoL)…
Summary · context
Adults with obesity (79.3% female; 54.0% white; 44.7% black; mean age = 47.6 ± 11.8 years and body mass index = 38.4 ± 4.9 kg/m² ) were randomized to IBT-alone (n = 50), IBT-liraglutide (n = 50) or Multicomponent (n = 50).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3169153105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.